Last
Update:
November 08, 2016
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
|
XX International AIDS Conference |
| |
T.E. Diphoko, S. Gaseitsiwe, V. Maiswe; et al
Abstract
E138A prevalence driven by cytotoxic T lymphocyte escape
in an HIV-1 subtype C infected population: implications
for rilpivirine-containing combination antiretroviral
therapy
S. Gaseitsiwe, C. Stangl, T. Diphoko, et al
Abstract
STaR study: single-tablet regimen
rilpivirine/emtricitabine/tenofovir DF maintains
non-inferiority to efavirenz/emtricitabine/tenofovir DF
in ART-naïve adults through W96 with a favorable safety
profile for abnormal dreams and dizzinessC.
Cohen, M. Bloch, D. Wohl, et al
Abstract
-
POSTER
Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 non-B
subtypes infected patients failing to non-nucleoside transcriptase
inhibitor-based therapies in Mali
A.I. Maiga, F. Dao, A. Balde, . et al
Poster
Abstract-
POSTER
STaR study: single tablet regimen rilpivirine/emtricitabine/tenofovir DF has
non-inferior efficacy compared to efavirenz/emtricitabine/tenofovir DF and
improves patient reported outcomes
C. Cohen
Poster
Abstract-
POSTER
Rilpivirine resistance mutations
in HIV-infected pregnant women
D.M. Cecchini, I. Zapiola, S. Fernandez Giuliano, et al
Poster
Abstract
-
Resistance analysis at
week 48 in virologically-suppressed subjects switching to RPV/FTC/TDF
single-tablet regimen (studies GS-US-264-0106 and GS-US-264-0111)
S.K. Chuck, D.P. Porter, R. Kulkarn, et al
Abstract
-
Thermosensitive gel
delivery of rilpivirine nanoparticles prevents vaginal HIV-1 acquisition
J. Long, C. Destache, M. Swanson, et al
Abstract
-
Renal
safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) and
cobicistat-boosted protease inhibitor regimens in HIV-1-infected patients
with mild to moderate renal impairment
F. Post, J. Andrade Villanueva, M. Fisher, et al
Abstract
-
Subgroup analyses of 96-week efficacy and safety of
elvitegravir/cobicistat/emtricitabine/tenofovir DF
D. Cooper, A. Zolopa, J. Rockstroh, C. Orkin
Abstract\
-
Safety and tolerability of switching from twice daily raltegravir plus
truvada to STRIBILD in virologically suppressed, HIV-1-infected subjects at
week 24
G. Crofoot, R. Ortiz, A. Mills, et al
Abstract
-
Two cases of breast
tenderness and female hormone fluctuations in women of child-bearing age
starting Stribild (FTC/TDF/COBI/ELV)
S. Scholand, R.D. Bruce|
Abstract
|
XIX International AIDS Conference |
| |
| |
Rilpivirine and
etravirine resistance among HIV-1 subtype C infected children failing
non-nucleoside reverse transcriptase
inhibitor-based regimens in south India
S. Saravanan, M. Vidya1 R. Kantor, et
al
Abstract
|
| |
Similar
prevalence of baseline HIV-1 minority variants among responders and
virologic failures, as well as
increased detection of HIV-1 minority variants at treatment failure, in
rilpivirine patients from the ECHO
and THRIVE Phase III studies
L. Rimsky, V. Van Eygen1,J. Vingerhoets,
et al
Abstract
|
| |
Efficacy and
safety outcomes for rilpivirine (RPV) versus efavirenz (EFV) plus
emtricitabine/tenofovir DF (FTC/TDF)
in treatment-naïve, HIV-1-positive adults with baseline viral load ≤
100,000 copies/mL-pooled 48-week ECHO and THRIVE
analysis
G. Behrens, B. Rijnders, M. Nelson, et
al
Abstract
|
| |
Initial
tolerability of rilpivirine (RPV, TMC278) and efavirenz (EFV) in the phase
III ECHO and THRIVE trials:
profile of grade 1 events
B. Rashbaum, P.-M. Girard, A. Rachlis.
et al
Abstract
|
| |
Prevalence of
rilpivirine resistance-associated mutations (RAMs) in U.S. samples
received for routine resistance testing
G. Picchio, L. Rimsky V. Van Eygen, et
al
Abstract |
|
XX
International AIDS Conference
Rilpivirine Main Page